No Data
No Data
J-Front, 24/2 operating profit up 125.9% to 43 billion yen, 25/2 forecast down 12.9% to 37.5 billion yen
The financial results for the fiscal year ending 2024/2 announced by J-Front <3086> were sales revenue of 407.0.06 billion yen, up 13.2% from the previous fiscal year, and operating profit of 43,048 billion yen, up 125.9% from the same period. Although the effects of the COVID-19 infection have been prolonged, major management numerical targets, including consolidated operating profit targets set in the mid-term plan, were generally achieved, and the financial position was improved by reducing interest-bearing debt, etc. As for the fiscal year ending 2025/2, sales revenue increased 3.6% from the previous fiscal year to 421.5 billion yen, and operating profit decreased 12.9%
AFC HD AMS Life Science 1H Net Y641.00M Vs Net Y414.00M
AFC-HD AMS Life Science Co. Ltd. (2927.TO) Japan 1st Half Ended February 29 GROUP 2024 2023 Revenue Y14.54 bln Y12.44 bln Operating Profit
J front, TKP, Shochiku, Toho (15 days)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------4/15 (Mon) <135A>VRAIN <1887>Japan Land Development <2292>S Foods <2337>Ichigo <2338>Quantum S <2404>Tetsujin HD <2484>Delivery Hall <2884>Yoshimuraf
Chiyo Kaken, etc. [Myomi brands seen from changes in turnover]
Stock closing price turnover compared to the previous day*<6579>Logley 546 8 321100*<7919>Nozaki Seal 164 5 1501900*<5724>Asaka Riken 1095 55 256600*<5133>Terilogy HD 301 2 965400*<3779>J-SCOM HD 150 8 1712500*<2927>AFC
Merchant, Rohm, Manny, etc
Significant continued growth. An upward revision of the first half earnings forecast was announced the day before. Operating profit was raised from the previous forecast of 770 million yen to 1.02 billion yen, up 50.9% from the same period last year.
AFC-HD is ranked and the first half earnings forecast is revised upward
AFC-HD <2927> is in the ranking (as of 9:32). Significant continuous growth. After the transaction ended the day before, the first half earnings forecast was revised upward, and it seems to be a source of buyers. Operating profit is expected to be 1,023 million yen (up 50.8% from the same period last year). That's up about 32% from the previous forecast. The domestic healthcare business and pharmaceutical business remained steady. The full-year forecast has not been revised. Operating profit for the fiscal year ending 2014/8 is expected to be 1,801 billion yen (up 10.1% from the previous fiscal year). Turnover rate increase
No Data